Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.
Patient’s mother gives back to Dana-Farber patients through nursing
more ›
May 05, 2023
Dana-Farber’s art curator brings wonder of art to patients
more ›
May 03, 2023
Honoring Asian American and Pacific Islander Heritage Month
more ›
Research and Patient Care
April 16, 2023
New research from Dana-Farber suggests that personalized education, coaching, and supportive resources could improve access to precision medicine by lowering the barriers to tumor genomic testing and clinical trial enrollment.
more ›
February 03, 2023
A novel antibody drug-conjugate therapy has been granted accelerated approved by the FDA for the treatment of metastatic HR+, HER2- breast cancer, based on the results of a Dana-Farber study.
more ›